Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
Researchers from Cedars-Sinai have discovered a genetic variation that raises the risk of perianal Crohn's disease, the most crippling form of the condition, in susceptible individuals.
Read Full NewsResearchers increasingly suggest that biological diversity within schizophrenia may limit efforts to identify a single defining biomarker.
Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.
1.
Recurrent UTIs impact eGFR in children with vesicoureteral reflux
2.
Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy
3.
Prostate cancer 'is not a death knell': Early detection and personalized care improve outcomes, study shows
4.
Guideline on management of early-stage non-small cell lung cancer released
5.
Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?
1.
Hypogammaglobulinemia: A Comprehensive Guide for Patients and Caregivers
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
4.
Engineering the Future of Oncology with CAR- Natural Killer Cell Design & Therapeutics
5.
Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge